Cryo-Cell International, Inc.
CCEL
$7.17
$0.14262.03%
| 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | 11/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 2.05% | 1.94% | 1.93% | 1.52% | 3.32% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.05% | 1.94% | 1.93% | 1.52% | 3.32% |
| Cost of Revenue | -34.47% | 41.93% | 39.14% | 39.56% | 37.93% |
| Gross Profit | 25.09% | -13.02% | -12.55% | -13.53% | -10.81% |
| SG&A Expenses | 7.89% | 9.41% | 8.64% | 9.61% | 10.19% |
| Depreciation & Amortization | -56.98% | -49.35% | -41.66% | -21.88% | 0.42% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.75% | 19.13% | 20.05% | 23.00% | 22.08% |
| Operating Income | 1,635.44% | -103.18% | -105.78% | -120.53% | -105.54% |
| Income Before Tax | 120.98% | -479.78% | -548.19% | -508.09% | -502.67% |
| Income Tax Expenses | 162.51% | -559.14% | -731.92% | -703.37% | -801.88% |
| Earnings from Continuing Operations | 104.22% | -456.17% | -505.57% | -459.64% | -443.58% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 104.22% | -456.17% | -505.57% | -459.64% | -443.58% |
| EBIT | 1,635.44% | -103.18% | -105.78% | -120.53% | -105.54% |
| EBITDA | 289.08% | -88.98% | -89.64% | -97.27% | -80.66% |
| EPS Basic | 104.14% | -460.18% | -513.21% | -467.26% | -452.23% |
| Normalized Basic EPS | 250.00% | -130.56% | -123.79% | -157.03% | -141.66% |
| EPS Diluted | 104.02% | -463.89% | -515.19% | -474.71% | -458.77% |
| Normalized Diluted EPS | 246.37% | -132.01% | -124.96% | -157.56% | -142.39% |
| Average Basic Shares Outstanding | -2.52% | -2.53% | -2.16% | -1.87% | -1.49% |
| Average Diluted Shares Outstanding | -1.91% | -1.92% | -1.60% | -1.95% | -2.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
